Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Letolizumab

Copy Product Info
😃Good
Catalog No. T77061Cas No. 1450981-87-9
Alias BMS-986004, BMS986004, BMS2h-572-633-CT-L2

Letolizumab (BMS-986004) is a dimeric antibody targeting CD40L for the expression of mutant IgG1 that lacks effector functions including Fc binding and complement binding.1 Letolizumab does not induce platelet activation in vitro and does not affect coagulation factors or platelet counts/function after repeated dosing in non-human primates.

Letolizumab

Letolizumab

Copy Product Info
😃Good
Catalog No. T77061Alias BMS-986004, BMS986004, BMS2h-572-633-CT-L2Cas No. 1450981-87-9
Letolizumab (BMS-986004) is a dimeric antibody targeting CD40L for the expression of mutant IgG1 that lacks effector functions including Fc binding and complement binding.1 Letolizumab does not induce platelet activation in vitro and does not affect coagulation factors or platelet counts/function after repeated dosing in non-human primates.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$169In StockIn Stock
5 mg$448In StockIn Stock
10 mg$715-In Stock
25 mg$1,080-In Stock
50 mg$1,460-In Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:98.8% (SDS-PAGE); 99.2% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information

Product Introduction

Bioactivity
Description
Letolizumab (BMS-986004) is a dimeric antibody targeting CD40L for the expression of mutant IgG1 that lacks effector functions including Fc binding and complement binding.1 Letolizumab does not induce platelet activation in vitro and does not affect coagulation factors or platelet counts/function after repeated dosing in non-human primates.
Targets&IC50
CD40L trimer (human):3.6 nM, CD40L trimer (non-human primate):3.8 nM, CHO-CD40L (human):1.3 nM, CHO-CD40L (non-human primate):7.3 nM
In vitro
Letolizumab inhibited the viability of CD40L trimer and CHO-CD40L in human B-cells and in non-human primate B-cells with IC50 values of 3.6 nM and 1.3 nM, and 3.8 nM and 7.3 nM, respectively. [2]
In vivo
Letolizumab treatment at doses of 2, 10, and 20 mg/kg administered intravenously once a week for 10 weeks significantly prolonged the survival time of rhesus monkeys after kidney transplantation. [2]
SynonymsBMS-986004, BMS986004, BMS2h-572-633-CT-L2
Reactivity
Human
Application
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
Gene ID
Uniprot ID
TargetTNFSF5/CD40L/CD154
Chemical Properties
Molecular Weight38.99 kDa
Cas No.1450981-87-9
Antibody Information
IsotypeIgG1-AST-4xS
Storage & Solubility Information
Storagestore at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator

Keywords

Related Tags: buy Letolizumab | purchase Letolizumab | Letolizumab cost | order Letolizumab | Letolizumab in vivo | Letolizumab in vitro | Letolizumab molecular weight